Takeda Returns Selected Assets Under Bumpy Amgen Alliance
This article was originally published in PharmAsia News
Executive Summary
Takeda is unwinding another part of its broad 2008 alliance with Amgen for the Japanese development of a portfolio of molecules, returning rights to selected assets - including trebananib - as it continues to hone its strategic focus.